Y983Wlp5LE | 1973494-16-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 异喹啉及其衍生物
• 英文名称: Y983Wlp5LE
• 英文别名: (1R)-1-(1-isoquinolin-5-ylsulfonylpiperidin-4-yl)ethanamine
• CAS: 1973494-16-4
• 化学式: C₁₆H₂₁N₃O₂S
• 分子量: 319.4
• InChiKey: MGLIYKZFLDTAMW-GFCCVEGCSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  22
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.44
• 拓扑面积：
  84.7
• 氢给体数：
  1
• 氢受体数：
  5

文献信息

• TREATMENT OF CEREBRAL CAVERNOUS MALFORMATIONS AND CEREBRAL ANEURYSMS WITH RHO KINASE INHIBITORS
  申请人：BioAxone BioSciences, Inc.

  公开号：US20160213664A1

  公开（公告）日：2016-07-28

  Provided are methods of treating a cerebral cavernous malformation (CCM) and methods of treating cerebral aneurysm in a mammal with certain Rho kinase inhibitors.

  提供了使用某些Rho激酶抑制剂治疗哺乳动物脑部海绵状血管畸形（CCM）和脑动脉瘤的方法。
• Treatment of cerebral cavernous malformations and cerebral aneurysms with rho kinase inhibitors
  申请人：BioAxone BioSciences, Inc.

  公开号：US10857157B2

  公开（公告）日：2020-12-08

  Provided are methods of treating a cerebral cavernous malformation (CCM) and methods of treating cerebral aneurysm in a mammal with certain rho kinase inhibitors.

  本文提供了用某些 rho 激酶抑制剂治疗脑海绵畸形（CCM）的方法和治疗哺乳动物脑动脉瘤的方法。
• Rho kinase inhibitor BA-1049 (R) and active metabolites thereof
  申请人：BioAxone BioSciences, Inc.

  公开号：US11198680B2

  公开（公告）日：2021-12-14

  BA-1049 (R) and its active metabolite are disclosed. Also disclosed are pharmaceutical formulations containing BA-1049 (R) or its active metabolite.

  本研究公开了 BA-1049 (R) 及其活性代谢物。还公开了含有 BA-1049 (R) 或其活性代谢物的药物制剂。
• RHO KINASE INHIBITOR BA-1049 (R) AND ACTIVE METABOLITES THEREOF
  申请人：BioAxone BioSciences, Inc.

  公开号：US20170313680A1

  公开（公告）日：2017-11-02

  The disclosure provides rho kinase inhibitor BA-1049(R), an hydroxy metabolite of BA-1049(R), and adipate salts and deuterated forms thereof, useful for treating CNS disorders and injuries.
• KINASE INHIBITORS FOR TREATMENT OF DISEASE
  申请人：BioAxone BioSciences, Inc.

  公开号：US20190015404A1

  公开（公告）日：2019-01-17

  Disclosed are therapeutic compositions including BA-1076 and/or BA-2057, methods of their use in the treatment of ophthalmological disorders. The therapeutic compositions may further include an IOP-lowering prostaglandin. The methods may further include administration of an IOP-lowering prostaglandin.